Objectives and setting-To determine the cost effectiveness of screening for glaucoma. Methods-Information on treatment efficacy, diagnostic methods, epidemiological characteristics of glaucoma, and costs were determined from the literature, from administrative databases, and from experts. Scenarios with different screening frequency, age, participation in screening, compliance with treatment, treatment efficacy, and diagnostic tests were examined.
Primary open angle glaucoma, referred to hereafter simply as glaucoma, is a disease which is characterised by progressive destruction of the optic nerve fibres. There is a gradual loss of visual function that can lead to blindness. Glaucoma cannot be cured, but an early diagnosis followed by appropriate treatment can, according to expert consensus, often slow down or interrupt its progression. The object of screening is therefore to prevent or to postpone the occurrence of blindness through early identification and treatment of cases of glaucoma or of subjects who are at high risk of glaucoma because of high intraocular pressure.
The costs and effectiveness of a programme depend on factors such as the frequency with which screening is carried out, the age range of the population to be tested, and the tests which are used. Each of these can be arbitrarily decided. Programme effectiveness, however, will also depend on the participation of the population in screening, the compliance of those who require treatment, and the efficacy of the treatment given. Such factors have to be assumed. Other necessary information, such as the incidence and prevalence of glaucoma in the population in question, of blindness due to glaucoma, and of high intraocular pressure requiring treatment, can be derived from data collected elsewhere.
The key factor in such an analysis, the efficacy of treatment, is unknown. Currently available results from randomised trials of treatment conducted during the 1980s are ambiguous' and although several other randomised trials have been launched, none is nearing completion at this time. There is, therefore, no immediate prospect of accurate estimates of the efficacy of treatment becoming available. Theoretically, the introduction of a formal screening policy should not even be considered until the efficacy of available treatments has been firmly established. However, although the efficacy of treatment has not been proved, there is an overwhelming consensus that it is effective'" and, in consequence, a belief that a programme of early detection and treatment of glaucoma would prevent blindness and should be started.
In response to such pressures, the Quebec health ministry recently requested the Conseil d'evaluation des technologies de la sante du Quebec to estimate the cost and health outcomes that might be associated with glaucoma screening programmes.' This paper describes the approach taken in that study. It considers first the key input variable which determines outcome-the efficacy of treatment of glaucoma. Next, it considers factors such as the screening strategy to be used, the age of the population to be screened, and the probable incidence and prevalence of glaucoma, high intraocular pressure, and glaucoma blindness in the target population. Finally, it considers the health benefits and costs of different screening strategies and the cost effectiveness ratios which might result.
Although the analysis is carried out in the context of the Canadian health care system, specifically in the province of Quebec, sufficient detail is supplied for the method and the results to be easily modified for application in other jurisdictions.
Efficacy of treatment of glaucoma
What is the probability that treatment of glaucoma and high intraocular pressure will prevent blindness? All glaucoma treatments aim at decreasing intraocular pressure. Drugs are usually prescribed first; the main agents currently in use are p blockers such as timolo!' Medical management is then supplemented, as necessary, by laser trabeculoplasty and surgical trabeculectomy. It is well established that such treatments are successful in decreasing intraocular pressure. However, the efficacy of this pressure reduction in preventing or postponing the development of blindness due to glaucoma has not been well demonstrated.
A review of this question in 1988 by the office of technology assessment of the United States Congress concluded that treatment of high intraocular pressure and of glaucoma is probably effective." Their report added, however, that justification for the current mode of treatment "is based on theory, personal experience, and the postulates shared among physicians rather than on direct evidence documented in the literature". 3 In a meta analysis of studies published between 1975 and 1991, Rossetti et al identified only three randomised treatment trials providing data on visual field changes. I Each used topical timolo!. Two of these three studies suggested that treatment with timolol was effective (P value 0.055 5 and 0.07 6 ) , while the third" did not demonstrate any beneficial effect. In a pooled analysis of these three studies the proportion of visual field loss was 25% lower after treatment with timolol than after a placebo (odds ratio 0.75; 95% confidence interval 0.42 to 1.35). These data therefore suggest benefit but are also compatible with an absence of treatment efficacy.
Three points concerning these reports should be noted. Firstly, the effect studied was not blindness, but the loss of visual fields. No randomised study of the prevention of blindness is currently available. Secondly, treatment efficacy was tested only among subjects with high intraocular pressure, without a diagnosis of glaucoma. No randomised study of the efficacy of treatment of glaucoma, whether associated with high, low, or normal pressures is available. Thirdly, only the effect oftimolol was investigated and the decrease in intraocular pressure achieved by this means was smal!. Intraocular pressure was, on average, only 3 mmHg lower in timolol treated eyes than in placebo treated eyes. Although it is possible that a treatment protocol aiming at the maintenance of greater pressure reduction, using when necessary treatment by laser and by surgery, would more effectively arrest visual field loss," this has never been shown in randomised trials.
ISS
Other indirect evidence supports the hypothesis that treatment can be effective. Thus in one uncontrolled study of 20 patients with glaucoma there was less progression of glaucoma in those patients in whom the pressures were most effectively reduced.B In a review of the issue in 1992 the American Academy of Ophthalmology concluded that "Animal work and a variety of clinical observations strongly suggest that lowering lOP [intraocular pressure] will prevent or retard further optic nerve destruction in a majority of patients","
Thus, for the purpose of these analyses, we have assumed that blindness due to glaucoma can be prevented by treatment that effectively lowers intraocular pressure. The probability that it will do so--that is, the level of efficacy of such treatment, is unknown. After consideration of the indirect evidence and the weight of expert opinion, we have at first presumed an efficacy of 50% and then considered values of 30% and 70% in sensitivity analyses. Our method of estimation of cost effectiveness ratios is given in sufficient detail in this paper to allow readers to insert any other estimate of their choice, including for example a 100% efficacy.
Determinants of outcome of screening
In addition to treatment efficacy, the following input variables would determine the health outcomes and the costs of organised screening:
DIAGNOSIS
The diagnosis of primary open angle glaucoma requires funduscopy, tonometry, gonioscopy, and perimetry. We considered the use of these tests in two different screening strategies. In the first, the initial examination included funduscopy and tonometry. Only in those subjects in whom at least one of these two tests showed an abnormality was gonioscopy and perimetry then performed. In the second strategy, the initial examination comprised only tonometry; funduscopy, gonioscopy, and perimetry were then carried out among subjects with a high intraocular pressure. The second approach is less expensive but allows only the detection of cases with high intraocular pressure, whereas the first strategy, which costs more, will detect both high and low pressure glaucoma.
AGE
Two age groups were considered for the screening programme: 40-79 years and 65-79 years. Under the age of 40 the prevalence of glaucoma and of high intraocular pressure is very low and blindness due to primary open angle glaucoma practically unknown. Thereafter the prevalence increases with increasing age and, as will be seen below, a programme which starts only at age 65 will miss some younger cases. However, by focusing on a high prevalence population a programme will be more cost effective. The upper age limit was set at 79 years. Because of the slow progression of this disease and the short life expectancy at this age, we assumed that all cases of glaucoma leading to blindness could be detected before subjects reach the age of 80.
EPIDEMIOLOGICAL DATA
In Quebec in 1991 there were 2 607 210 individuals aged 40-79 and 619270 between the ages of 65 and 79. 9 Other necessary data were estimated on the basis of studies carried out outside Quebec. Table 1 summarises these data; the methods of estimation are summarised in appendix 1. both assumed to be 75%, and treatment efficacy 50%. The number of cases of blindness prevented in the steady state will be the number of cases of blindness without screening, 1260, multiplied by (0.75) x (0.75) x (0.5), which corresponds to 354 cases.
SCENARIOS 2, 3
In these two scenarios the only difference from scenario 1 is that screening is carried out at one and five year intervals, respectively. It is assumed that these changes would not influence the annual detection rate or the efficacy of treatment, an assumption which may well be optimistic for the five year screening cycle. Appendix 2 presents further considerations about the appropriate screening frequency. SCENARIOS 4-9 These scenarios explore the impact of varying rates of participation, compliance with treatment, and efficacy of treatment on the reduction in blindness prevalence.
Health benefits of glaucoma screening
The health benefits were estimated in terms of the reduction in prevalence of blindness resulting from screening. Blindness is defined as central visual acuity 20/200 or less in the better eye with best correction, or widest diameter of visual field subtending an angle of no greater than 20 degrees. 10 The full benefits of the screening programme, in terms of prevalence reduction, will only be attained when the population has been subjected to screening for a period as long as the maximum life expectancy at onset of blindness. This prevalence reduction, because it is permanently maintained in the steady state population, can be expressed as a reduction in the years of blindness experienced in the population each year. The influence of different input variables on the steady state number of years of blindness prevented was then explored. The variables were studied in different combinations (table 2) . SCENARIO 1 For this scenario it is presumed that screening is carried out every three years using both funduscopy and tonometry. The participation in screening and compliance with treatment are In this scenario, screening is restricted to subjects aged 65-79. The prevalence of blindness without intervention in this population would be 1021 cases and the number of cases of blindness prevented, if all other variables of scenario 1 applied, would be only 287. Thus, modifying input variables over a wide range, as explored in these scenarios, changes the amount by which the prevalence of blindness is reduced by between 213 and 496 cases. SCENARIOS 11, 12 These scenarios envisage screening programmes in which only tonometry would be used for the initial screening. In 30% of cases of glaucoma, intraocular pressure is low or normal. Such cases would be missed by this screening strategy (in subjects aged 65-79, 27% would be missed). Accordingly, the number of cases of blindness prevented, if any of the strategies were modified in this way, would correspond to 70% of the number when both funduscopy and tonometry are used as initial screening tests in subjects aged 40-79 and 73% in subjects aged 65-79. Modification of scenario 1 in this way would then result in 
Costs
In this analysis we estimated the net direct costs of a screening programme in steady state, seen from the point of view of the provincial government, which in Quebec is responsible for the health care system. These costs comprise the costs of screening tests and the costs of treatment of cases detected, less the costs of treatment and support of the blind, which would be avoided. All costs are expressed in Canadian dollars. We did not take into account in our calculations other costs which may be associated with " We did not include in this figure the incidence of glaucoma with high intraocular pressure; we presumed that these subjects would have been found by screening at an earlier point in their natural history, at the time of appearance of the high intraocular pressure. t Fee schedule for medical acts carried out in private offices. 11 screening programmes, such as fees and salaries for the personnel managing the programme, or costs associated with inviting the eligible population to be screened.
COST OF DIAGNOSIS
The order in which testing is carried out significantly influences the costs and health benefits of a programme. "Initial tests" are those to which the whole population at risk is submitted at one, three, or five year intervals according to the scenario selected, while ''follow up tests" are given only to those whose initial tests indicate abnormality. While the former are directly related to the frequency of screening cycles, the latter are not. They depend only on the number of cases detected. Table 3 gives an estimation of the cost of diagnostic tests associated with a yearly screening programme in which the initial eye examination includes both funduscopy and tonometry. The professional fees are based on those for medical specialists of Quebec, in 1994, for acts performed in a private office." These fees, as distinct from fees charged in hospitals, take into account not only professional honoraria, but also a component to cover office overheads. 404460  16716741  36385066  100000  2  51191 596  404460  16116141  74912191  208000  3  11558319  404460  16716741  28679520  78000  4  15411092  323568  13373393  29 108053  100000  5  23 116638  485352  20060089  43662079  100000  6  19263865  404460  13 313393  33041 118  114000  7  19263865  404460  20060089  39728414  90000  8  18263865  404460  16716741  36385066  168000  9  19263865  404460  16716741  36385066  70000  10  4389943  59760  8124917  12574620  42000  11  4901 554  468735  13 783 774  19154063  74000  12 1 121988 58139 6 583 477 7763604 36000 " The input variables for each scenario are indicated in table 2.
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If the entire Quebec population aged 40-79 was enrolled in the screening programme (see table 3 ) and was in steady state with respect to size, age, sex distribution, and incidence of high intraocular pressure and primary open angle glaucoma, there would at any time be a prevalence pool of 168 746 cases with detected high intraocular pressure, or glaucoma, or both (see table 1 ). The size of this prevalence pool would remain fixed over time, being constantly replenished through yearly screening activities.
It was assumed throughout that the numbers of cases of primary open angle glaucoma and of high intraocular pressure shown in table 1 were those detectable by screening. In other words, our estimates, because they were derived from previous population surveys, already take into account the imperfect sensitivity and specificity of screening tests.
As estimated in Similar estimations indicate that the cost of diagnostic tests performed every three years, for a programme limited to ages 65-79 and assuming a participation rate of75%, as in scenario 10, would be $C4 449 703.
The costs of screening programmes in which tonometry alone would be performed as the initial diagnostic test were estimated in see-narios 11 and 12. There is currently no professional fee in Quebec for a tonometry performed by an ophthalmologist. We therefore arbitrarily allocated a fee of $C8 for this test, which would be offered to the whole population concerned. This fee is comparable with fees paid for ophthalmological diagnostic procedures such as, for example, gonioscopy, examination with contact lens of fundus under dilatation, or specular microscopy. The follow up tests, in this case a complete eye examination ($C31.60), gonioscopy ($CI0), and perimetry ($C35), would then only be performed in subjects with high intraocular pressure. For a participation rate of 75%, the cost of diagnostic tests would thus be $C5 370 289 for subjects aged 40-79 and $Cl 180 127 for those aged 65-79.
COST OF TREATMENT
To determine the cost of treatment for the patients with glaucoma who are identified through screening, detailed information on the clinical course of the disease from diagnosis to death is required. Unfortunately, this kind of information is not available. It was therefore necessary to create a stylised representation of the clinical course on the basis of selected studies describing the clinical evolution of patients," 12-1. and the opinion of experts. Table  5 shows the hypothetical evolution offoilow up and treatment of 100 patients with glaucoma for a period of five years. According to this schema, during the first year all 100 patients will be treated with one drug only. During the second year, 15 of these patients will not respond sufficiently to treatment and will require a second drug. During the third year, 24 patients will require two drugs. As shown in table 5, the clinical course of the disease will continue to evolve during years four and five, with some patients requiring laser treatment and surgery. The cost of follow up and treatment of this hypothetical group of subjects over a five year period was then estimated based on the assumptions shown in table 6. Drug prices for 1993 were used, and professional fees for 1994. The total costs for 100 patients for five years, according to these assumptions, is $CI76576, or $C353 per patient per year.
For all years beyond the fifth year of follow up, we also used the figure of $C353 per patient per year. Lack of data on the representative clinical course of disease and the consequent high level of uncertainty involved precluded extension of this theoretical treat- I  100  0  0  0  0  0  0  100  2  85  IS  0  0  0  0  0  100  3  76  24  0  0  0  0  0  100  4  72  13  7  8  0  0  0  100  5  68  8  4  5  7  5  3  100   Total 401  60  II  13  7  5  3  500 Boivin, McGregor, Archer ment scenario beyond the fifth year. Probably, however, the actual costs for subsequent years will be higher than $C353 per year and this approach probably somewhat underestimated costs in relation to effectiveness. The costs of treating patients with high intraocular pressure without glaucoma were estimated using the following assumptions. According to Gottlieb et al, between 10 and 30% of these patients must be treated"; in order to favour, when in doubt, lower costs in relation to effectiveness, we assumed 10%. The cost of treatment of these subjects was assumed to be identical with the cost of treatment for those with glaucoma-that is, $C353 per year. It was also assumed that the 90% of subjects with high intraocular pressure who were not put on treatment would require closer observation, estimated to consist of two visits per year to their ophthalmologist, at a cost of $C63.20 per year.
The total treatment cost, for patients with glaucoma and those with high intraocular pressure, was thus estimated to be $C29 718 651 per year (see table 7 ). This cost includes two approximately equal components-that is, a component for glaucoma (57% of the total cost) and a component for high intraocular pressure (43% of the total cost). This estimate is sensitive to assumptions about prevalence of treated cases. If we change the assumptions made in table 7 and we presume, for example, that the correct estimate of prevalence of glaucoma is 60 000 cases and that 30% of cases of high intraocular pressure without glaucoma are managed as cases of glaucoma, the resulting cost is $C41 952470. The treatment cost is not affected by screening frequency. It would, however, be affected by the extent of participation in screening and of compliance with treatment. Ifboth of these unknowns were assumed to be 75%, our estimate of the total annual treatment cost would be (0.75) x (0.75) x ($C29 718 651) =$C16 716 741. We did not take into account in our calculations the fact that when patients become blind they do not Table 6 Assumptions used in estimation of the cost of follow up and treatment of the patients with glaucoma who are identified through screening * Subjects detected at ages 40-79 continue to be treated or followed up, and therefore continue to incur costs, at the age of 80 or more. We made the simplifying assumption that all prevalent cases at ages 40+, including those aged 80 or older, can be detected before the age of 80. This assumption probably led to a small overestimation of patients requiring treatment or follow up after screening at ages 40-79. require any further treatment for glaucoma. Such a correction would reduce the total treatment cost by a factor of less than 1%.
COST OF BUNDNESS
The cost of blindness was estimated in terms of costs of health care, of services, and of visual aids provided to the visually impaired or in their direct support by the provincial government. Such costs include assistance for reading, writing, and mobility, devices for the conversion of optical input into tactile impulses, Braille typewriters, canes, and guide dogs. The programme covers a range of visual handicaps, and not only blindness, or blindness due to glaucoma. We therefore had to assume that the costs for blind patients with glaucoma were identical with those for the average person benefiting from this programme.
The costs of this programme in 1992 varied from SC942 for subjects aged 40-44 to SC 193 for those aged 85 or more." These represent amounts paid by the provincial government for the purchase, adjustment, replacement, or repair of aids, or for the purchase and maintenance of dogs. To obtain an average cost we weighted the age specific costs by an estimate of the age specific distribution of the prevalence of blind cases in Quebec. The estimated average cost for each case of blindness was SC325 per year.
Other rehabilitation services include the assessment of visual function, the teaching of Braille and of the use of various communication devices, training in the use of a cane and a guide dog, instruction towards general autonomy in daily life, and psychological services. The budget allocated to the 10 rehabilitation centres of Quebec for 1993-94 was SC18 803 302, giving an average cost of $C1182 per person, which we assumed was applicable to blind subjects with primary open angle glaucoma. For subjects aged 65 or older, who are less likely to learn to use resources such as Braille, this probably is an overestimate. 159 Another cost to the state, though not to the health services, is the disability pension. The average pension paid in 1993 to persons under the age of 65 and with visual impairment due to glaucoma was SC8315 per year. The disability pension is replaced at age 65 by the universal old age pension plan. If we average out the cost for blind subjects before the age of 65 (SC8315 per year for 19% of all prevalent cases) with the null cost later (81% of the cases), the average pension becomes $C1580 per subject per year. Because disability pensions do not represent direct health services expenses it may be appropriate to exclude them from cost calculations. The impact of this exclusion would be to increase cost effectiveness ratios shown below, for subjects aged 40-79, by about $C1000.
The cost of special transport services or of home services provided by local community health centres, and the loss of governmental revenues associated with income tax reductions granted to blind people, were not included. Table 8 summarises estimates of the annual costs of blindness to the state. For all ages the total cost is SC3087 per year of blindness, and for those aged 65 or more, $C1393. These figures are approximate and in subsequent calculations they are rounded to $C3000 and $C 1500 respectively. These costs are small relative to the costs of screening, and even large errors in these estimates would have little effect on our cost effectiveness analyses.
Cost effectiveness
Using the above estimates we next calculated the cost effectiveness ratios of the various scenarios already considered in table 2. The results are presented in table 4. Estimations of the cost effectiveness of screening programmes using funduscopy and tonometry at the time of the initial eye examination are shown in scenarios 1 to 10.
Scenario 1 is based on three-yearly screening of subjects aged 40-79, with participation in screening and compliance with treatment both assumed to be 75%, and treatment efficacy assumed to be 50%. In the steady state this programme would cost $C36.4 million per year and there would be a reduction of 354 cases in the prevalence of blindness, which would translate into a cost effectiveness ratio of $CIOO 000 per year of blindness avoided.
Scenario 2, based on the same hypotheses as scenario 1, with annual screening, would represent a cost of SC74.9 million per year, and a cost effectiveness ratio of SC208 000 per year of blindness prevented. Scenarios 3 to 9 examine the impact of variations of: screening frequency (scenario 3); participation in screening (scenarios 4 and 5); compliance with treatment (scenarios 6 and 7); and treatment efficacy (scenarios 8 and 9). If it were shown that the frequency of screening could be reduced to once every five years without loss of efficacy, the cost effectiveness ratio would be SC78 000 per year of blindness. If treatment efficacy were to be as high as 70% (scenario 9), the cost effectiveness ratio would become SC70 000 per year of blindness prevented.
Scenario 10 which considers a programme restricted to subjects aged 65-79 results in a cost effectiveness ratio of SC42 000 per year of blindness prevented. It would at the same time only prevent 287, instead of 354, cases of blindness.
We assumed in these calculations that subjects who have a diagnosis of high intraocular pressure, or glaucoma, or both, at age 65, but who are not yet blind, will benefit as much from their treatment as subjects whose treatment was undertaken earlier, as in scenario 1. This means, for example, that in a patient whose glaucoma became detectable at age 57, and who was not yet blind at age 65, treatment efficacy was the same, whether treatment began at age 57 or at age 65. This assumption is questionable and probably leads to an overestimation of programme effectiveness in screening restricted to older subjects. Scenarios 11 and 12 explore screening programmes in which tonometry alone would be performed as the initial diagnostic examination. In scenario 11 tonometry would be offered to subjects aged 40-79 every three years. This scenario would prevent 248 cases of blindness, for a cost effectiveness ratio of SC74 000 per year of blindness prevented. In scenario 12 the same programme is restricted to subjects aged 65-79, for a cost effectiveness ratio of SC36 000 per year of blindness prevented. This would lead to the prevention of 209 cases of blindness each year, which represents 59% of the number which would be prevented with scenario 1.
At present the efficacy of treating low pressure glaucoma is more in doubt than is the efficacy of treating high pressure glaucoma. If treatment of low pressure glaucoma were eventually shown to be ineffective, the selective detection of high intraocular pressure by this strategy would render it relatively efficient.
We have throughout considered the installation of an organised screening programme. However, with very minor adjustments, the estimates of cost effectiveness apply equally to routine periodic screening carried out in the context of "case finding", when patients visit health professionals for other reasons.
IMPAIRED VISION
All the scenarios discussed above used complete blindness as the health outcome targeted by treatment. However, any treatment which is effective must also prevent a period of impaired vision which normally precedes blindness. We have made no attempt to equate a year of impaired vision with some fraction of a year of blindness, and it should be borne in mind that as a result of ignoring impaired vision, all estimates of cost effectiveness somewhat underestimate the effectiveness of each scenario tested. DISCOUNTING Throughout this analysis it has been assumed that the onset of treatment efficacy was immediate-that is, that once given, a treatment presumed, for example, to be 50% effective immediately started to arrest the progression of the disease process in 50% of the subjects. Thus from the perspective of the health care system, each annual investment made would lead to an immediate reduction of the prevalence of blindness. Since from this viewpoint costs and effectiveness are contemporaneous, neither was discounted. This perspective remains identical with different screening frequencies. For example, with a screening cycle of three years, screening is actually offered to one third of the population each year. This activity continuously replenishes the pool of treated subjects, who then benefit immediately from treatment.
Conclusion
The Canadian Task Force on the Periodic Health Examination and the United States Preventive Services Task Force reviewed the question of routine periodic screening for glaucoma among subjects over the age of 65. 19 The Canadian Task Force graded the available scientific evidence as weak and recommended that no screening be performed. The American Task Force recommended regular screening by an eye specialist, either an ophthalmologist or an optometrist. Gooder assessed the evidence for the cost effectiveness of screening for glaucoma in the United Kingdom." She indicated that the treatment of glaucoma is probably effective but that this remains uncertain; she assumed in her analyses that treatment reduced the number of years of blindness in screened subjects by 50%. Her estimate of cost utility was £22 000 per disability adjusted life year saved. She concluded that a case finding approach by trained optometrists in those aged 40 or older would represent a more rational policy than screening.
On the basis of this review, we conclude that the best data currently available suggest that all the different screening programmes commonly envisaged would lead to high costs relative to the health gains achieved. The most likely screening programme to be undertaken, involving funduscopy and tonometry as initial diagnostic tests, offered every three years to individuals aged 40 to 79, would result in an estimated cost effectiveness ratio of SC 100 000 per year of blindness prevented. This estimate is insensitive to the rates of participation and compliance but is highly sensitive to estimates of efficacy of treatment. However, even if treatment efficacy were assumed to be as high as 70%, the cost effectiveness of such a programme would still be SC70 000 per year of blindness prevented.
Our cost estimates for the screening programme included all costs incurred for screening tests and all costs for treatments. We did not take into account the fact that in the absence of screening, some subjects would eventually develop symptoms leading them to consult and to be treated. Because these costs would be incurred even in the absence of screening they should have been subtracted from our estimates of the costs of screening. However, since most West European and North American populations receive some level of screening in the form of case finding, empirical estimates of what the diagnostic and treatment costs would be in the absence of screening are not available. However such a correction could only have a trivial impact on estimates of the cost effectiveness ratios.
For example, in scenario 1 (table 4, line 1), the total cost was SC36 385 066. Of this amount, the cost of the initial and follow up tests-that is, SC 19 668 325, must be totally assigned to the screening programme. We estimated in table 7 that the treatment costs can be broken down into two approximately equal components-that is, 57% of the costs for the treatment of glaucoma, and 43% for high intraocular pressure. Ifwe apply these percentages to the treatment costs for scenario 1 (table 4, line 1), the costs related to cases of high intraocular pressure without glaucoma (asymptomatic patients who would not be under care in the absence of screening) would be approximately 43% of SC16 716 741, or SC7 188 199; the costs for treatment of cases with glaucoma would be SC9 528 542. We can only speculate as to what proportion of the latter figure (SC9 528 542) would be spent in the absence of screening. Our assessment of the natural history of glaucoma suggests that patients live about 18 years between the diagnosis of screen detected glaucoma and the diagnosis of blindness. We know that in the absence of screening the disease may be severely advanced and the patient almost blind before it is diagnosed." If we therefore arbitrarily assign one third of the natural history of the disease-s-that is, six years, to the symptomatic phase, the sum of SC3 176 181 (= 33.3% of SC9 528 542) should be deducted from the costs of screening to estimate the net cost of screening versus no screening. The cost of scenario 1 would thus become SC33 208 885 (as opposed to SC36 385 066) and the cost effectiveness ratio would be reduced from SC 100 000 per year of blindness avoided to SC94 000, a change which would influence the overall conclusion of our analysis very slightly.
We assumed throughout our analyses that the screening programme under consideration had attained a steady state. This means that the size of the screened population and its distribution by risk factors for glaucoma and high intraocular pressure are fixed, and that the population has been subjected to screening for a period at least as long as the maximum life 161 expectancy of a patient at onset of blindness. 21 The steady state model represents a useful tool for the analysis of complex population phenomena, but it also presents several limitations. Demographic projections suggest, for example, that the actual size of the Quebec population aged 40-79 might be 48% larger in 2011 than in 1991, with a modified age distribution." The present estimates predict therefore the situation which would pertain if the 1991 population had been regularly screened in the past. It should not be considered a forecast of the situation which is likely to pertain in 20 years'time.
Comparison of cost effectiveness analyses carried out by different authors in different jurisdictions should only be undertaken with great caution. However, the estimates arrived at here can reasonably be compared with the estimate of SC4500 per year of life gained from breast cancer screening of women aged 50 to 69, or the estimated SC14 500 per year of life prolonged by a programme of cardiac transplantation, recently carried out in Quebec by the Conseil d'evaluation des technologies de la sante du Quebec." 2.
In the final analysis, however, policy decisions depend on factors other than cost and cost effectiveness. None the less, it is clear that these estimates of effectiveness and costs, even of the limited glaucoma screening programmes considered, provide little support for such initiatives when compared with other demands on health care resources with more favourable cost effectiveness ratios.
Appendix 1: Estim.ation of epidemiological parameters
PRIMARY OPEN ANGLE GUUCOMA To estimate the prevalence of primary open angle glaucoma in Quebec, age-sex specific rates from an epidemiological study carried out in Beaver Dam, Wisconsin 25 were applied to the 1991 Quebec population. The age-sex adjusted estimate for Quebec, for ages 40-79, was 40 901 cases + 2 607 210 persons, or 1.57%. Estimates of prevalence of glaucoma with high intraocular pressure and with normal pressure were also obtained with the same approach (table 1) .
We used the method of Leske et ai" to estimate incidence of glaucoma in Quebec based on the Beaver Dam prevalence data and the Quebec population. Ten-year incidence rates were estimated as (P x + 10 -P x ) + (1 -P x ) , where P x represents prevalence at a given age. The annual incidence of primary open angle glaucoma for ages 40-79 was estimated to be 2715 cases/year.
HIGH INTRAOCULAR PRESSURE
To estimate the overall prevalence of high intraocular pressure in Quebec we used data from two recently published reports, presenting data from Baltimore" and from Beaver Dam. 25 The prevalence rates of high intraocular pressure were, in Baltimore, 7.42% of all eyes examined," and in Beaver Dam, 4.7% of all right eyes. 25 Because prevalence rates were for eyes, not persons, the actual prevalence rates for subjects with at least one eye affected would be somewhat higher than the estimate of 4.7% (Beaver Dam) and somewhat less than that of 7.42% (Baltimore), but no quantitative information is available on this. These represent the crude prevalence rates for high intraocular pressure observed in these populations, not adjusted for the age distribution of the Quebec population. A comparison of the age distributions of these two populations with the age distribution for Quebec in 1991 shows, however, that the Quebec population was younger. This means that age adjusted estimates for Quebec would be somewhat lower than these crude values. We accordingly based our estimate approximately mid-way between these two estimates. The prevalence rate for high intraocular pressure for Quebec was thus estimated to be 6%. This value yields 156433 persons aged 40-79 (6% of 2607210 persons) with intraocular pressure> 21 mmHg in Quebec, with or without glaucoma. The Baltimore and the Beaver Dam reports did not give sufficient details to derive age specific prevalence rates. We therefore used data provided by Gottlieb et al," who estimated age specific prevalence rates of high intraocular pressure based on the average of rates reported in 34 studies published between 1951 and 1979. We took the grand total of cases for Quebec-that is, 156 433, as fixed, and we rescaled the estimates provided by Gottlieb et al accordingly. We also calculated the prevalence of high intraocular pressure without glaucoma, subtracting from the estimate of 156433 cases (prevalence of high intraocular pressure) the previously calculated estimate of prevalence of glaucoma with high intraocular pressure (28 588 cases, Using the institute data for 1989, we also calculated that the average age at diagnosis of blindness, among subjects aged 40 and older, was about 78. The average expectation oflife in Canada at age 78, for men and women combined, is about nine years. When mathematical relationships between prevalence, incidence, and average duration of disease were used," the prevalence of blindness due to primary open angle glaucoma in Quebec was thus estimated as (140 cases/year) x (9 years) = 1260 cases.
To obtain an estimate of the prevalence of blindness among subjects aged~65 we used data published by Hiller and Kahn on the prevalence of blindness due to glaucoma among white subjects in 14 American states in 1969-70.'°The rates estimated by these authors suggest that 81 % of the prevalent cases of blindness are found in subjects aged~65. When this percentage is applied to the estimate of 1260 prevalent cases in Quebec this translates into (0.81) x (1260 cases) = 1021 cases in subjects aged~65 .
Appendix 2: The frequency of screening The optimal screening frequency depends on the natural history of the disease. The shorter the time span between disease onset and incidence of blindness, the more frequent must screening be. Unfortunately, our knowledge of the natural history of glaucoma is very limited. In three randomised trials of the treatment of glaucoma.r" an average of 3% of patients or, depending on the study, 3% of eyes, experienced a loss of visual fields each year. In another randomised trial it was found that among patients in whom visual fields were already restricted at the time of randomisation, 32% had deteriorated during the following year, against 8% who had improved.'
Other investigators determined disease progression in samples of patients followed up in certain clinics. In a cohort of 73 patients followed up for 10 years, Hart and Becker noted that 78% of eyes that started with a single hemifield affected had dense or absolute loss of visual field within the originally affected hemifield, and 18% had intermediate levels of 10ss.31 Of 13 eyes that had had both altitudinal hemifields affected simultaneously at the start of the follow up, all had developed absolute or dense visual field loss in both hemifields.
On the basis of their clinical judgment and a review of the literature, Gonlieb et al concluded that patients with untreated high intraocular pressure who develop visual field loss will become legally blind 12.5 years after screening." This interval would include five years to initial field loss plus 7.5 years to legal blindness after initial field loss.
These observations all concern patient populations chosen because they presented high intraocular pressures. It is plausible that a large proportion of cases of blindness will occur in patients with glaucoma whose intraocular pressure is normal. We do not know whether among these patients the disease evolves at the same pace as among those with high pressure. Various other selection biases can also affect data arising from clinical samples, making their interpretation difficult. It is conceivable, for example, that clinical samples include more patients with a poor prognosis than a randomly selected sample of all patients with glaucoma.
Epidemiological data offer another perspective on this question. We estimated that the average age of new cases of high intraocular pressure in the Quebec population was SO; for new cases of primary open angle glaucoma the average age was 60; and for new cases of blindness, 78. These figures suggest that the natural history of the disease is quite prolonged. Possibly, however, a bias exaggerating the duration of the natural history was present in this analysis. The estimation of the average age at blindness was based on data from patients who were probably treated before becoming blind; the average age of interest would have been the age of untreated blind patients, reflecting more accurately the actual natural evolution of the disease. Despite this, this analysis suggests a long latency. If treatment were known to be effective even when given late in the disease evolution, and if the strict objective of screening were the prevention of legal blindness, the screening interval might be very long, perhaps five to 10 years.
In summary, the available data on the natural history of glaucoma are fragmentary, contradictory, and possibly biased. Our judgment is that a three year screening interval represents the best choice. We feel that this is justified because screening must be carried out sufficiently often to prevent not only blindness but also the loss of visual fields. On the other hand, screening should probably not be carried out more frequently as the available epidemiological data, even though not very rigorous, lead us to believe that disease progression towards blindness is not fulminant. 
